Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall and Forest to collaborate on LAS100977

Almirall and Forest to collaborate on LAS100977

21st December 2009

Almirall and its pharmaceutical partner Forest Laboratories have announced that they will collaborate to develop, manufacture and distribute the respiratory drug LAS100977.

The inhaled, once-daily treatment is a long-acting beta-agonist that has been developed by Almirall to treat bronchoconstriction in asthmatic patients.

Now, the firm will work with Forest to develop the treatment in combination with an undisclosed corticosteroid using Almirall’s proprietary Genuair inhaler for the treatment of both asthma and chronic obstructive pulmonary disease.

Jorge Gallardo, chairman and chief executive officer of Almirall, said: “Extending our collaboration with Forest is an excellent opportunity to maximise the value of LAS100977 for patients and investors.”

Meanwhile, last week the organisation launched two new treatments for people who suffer from arterial hypertension.

These are Parapres Plus 32 and Parapres Plus Forte, which are indicated for patients with high blood pressure that cannot be sufficiently controlled with monotherapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.